X4 Pharmaceuticals Q3 revenue rises on XOLREMDI sales

Overview

• US rare hematology drug developer's Q3 revenue rose yr/yr, driven by higher XOLREMDI sales

• Net loss for Q3 narrowed from prior year

• Company secured $150 mln loan facility, cash runway expected into Q1 2029

Outlook

• Company expects to complete 4WARD trial enrollment in Q4 2026; topline data due Q1 2028

• First participant in 4STEPS Phase 2b trial expected to enroll in Q1 2027

• Company says cash runway extends into Q1 2029

Result Drivers

• LOWER R&D EXPENSES - Co said reduced headcount from 2025 restructuring led to lower R&D expenses

• LOWER G&A EXPENSES - Co attributed decrease in G&A expenses to reduced legal and compensation costs, and lower sales and marketing spend

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• Wall Street's median 12-month price target for X4 Pharmaceuticals, Inc. is $12.00, about 278.5% above its November 3 closing price of $3.17

Reuters Recommended Reads

• Nov 3 - Ultragenyx Q3 revenue rises, net loss narrows

• Nov 2 - Travere Q3 product sales nearly double on FILSPARI growth

• Nov 3 - Zevra Therapeutics Q3 revenue rises 45% on MIPLYFFA sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)